Prevalence of Multidrug Resistance and Extended-Spectrum \( \beta \)-Lactamase Carriage of Clinical Uropathogenic *Escherichia coli* Isolates in Riyadh, Saudi Arabia

Abdulaziz Alqasim,1 Ahmad Abu Jaffal,2 and Abdullah A. Alyousef1

1Microbiology Research Group, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia
2Department of Clinical Laboratory Sciences, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

Correspondence should be addressed to Abdulaziz Alqasim; aalqasim@ksu.edu.sa

Received 4 August 2018; Accepted 17 August 2018; Published 16 September 2018

1.Introduction

Urinary tract infections (UTIs) are among the most common bacterial infections acquired in community and hospital settings [1]. UTIs are a main cause of hospital admissions and are associated with high morbidity, mortality, and economic costs [2, 3]. Worldwide, it is estimated that UTIs affect about 150 million people each year, costing the global economy more than 6 billion US dollars [4]. UTIs occur in all age groups and in both genders [5]. However their incidence increases with age [6], and the annual incidence of UTIs in the elderly population ranges from 10% in the community to as high as 30% of hospitalized patients [2]. UTIs are more common in women than in men [7], with an estimated 50–60% of women suffering from at least one UTI during their lifetime [3].

It is well known that *Escherichia coli* (*E. coli*) is the main causative agent of UTIs [8], and the uropathogenic *E. coli* (UPEC) group have the capability of causing around 90% of community-acquired UTIs and up to 50% of nosocomial UTIs [9, 10]. Over the past two decades, UPEC strains have shown an increased level of antimicrobial resistance to frontline antibiotics such as trimethoprim-sulfamethoxazole and ciprofloxacin. Several surveillance studies during the 2000s
across Europe, North America, and South America have demonstrated that resistance to these antibiotics has been observed in as many as 20–45% of UPEC isolates [1, 11].

UPEC have also been associated with a high level of extended-spectrum β-lactamase (ESBL) gene carriage [12]. ESBLs comprise many plasmid-mediated derivatives such as TEM, OXA, and SHV [13]. Since 2000, a new group of ESBLs, called CTX-M (i.e., “active on CefoTaXime, first isolated in Munich”), has emerged [14]. Since then, CTX-M β-lactamases have been the predominant ESBL type worldwide [15]. Within the CTX-M family, CTX-M-15 is currently the most prevalent CTX-M genotype [14, 15]. This group of ESBLs has been associated with an extensive pattern of antimicrobial resistance to many antibiotics, including β-lactam agents such as penicillins, cephalosporins, monobactams, and carbapenems [16–19]. In addition, CTX-M-producing E. coli strains are often associated with co-resistance to other large antimicrobial families such as aminoglycosides and fluoroquinolones [19].

Since treatment of UTI is frequently started empirically, prior information on the prevalence of causative agents as well as the antimicrobial susceptibility profiles in a particular setting is essential [20]. However, the distribution of UTI causative agents and their antibiotic susceptibility profiles differs regionally [21, 22]. Therefore, the evaluation of the local etiology and antimicrobial susceptibility profiles is essential to achieve the most effective empirical therapy [8].

In Saudi Arabia, previous studies have been conducted to determine the prevalence of ESBL-producing Enterobacteriaceae (EPE), with CTX-M enzymes being the most common ESBL type [23–30]. However, there are a limited number of studies on the prevalence of ESBL-producing E. coli. Additionally, there are few detailed reports on characterizing the genotypes of ESBL enzymes that have been published.

This study aims at determining the antimicrobial susceptibility patterns of a collection of clinical E. coli urine isolates, to phenotypically assess the ESBL carriage of these isolates and to characterize the ESBL genotypes of these isolates. This study is important for providing clinicians with information required to facilitate the effective treatment and management of UTI patients.

2. Materials and Methods

2.1. Bacterial Isolates. One hundred nonconsecutive, non-duplicate clinical E. coli urine isolates were obtained from urine samples of inpatients hospitalized at a tertiary healthcare centre in Riyadh, Saudi Arabia. Midstream clean catch urine samples showing significant bacterial growth, of >10^5 colony-forming units (CFU/mL) with a single type of bacteria, were considered positive for UTIs. Urine isolates were collected over a period of 3 months from January 2018 to March 2018 and were identified as E. coli using the Vitek 2 identification system (Vitek2-ID-GNB, BioMerieux). The isolates were stored at −80°C in Luria Bertani broth (HiMedia Labs, India) with 20% glycerol (v/v).

2.2. Antimicrobial Susceptibility Testing. Antimicrobial susceptibility testing (AST) for all isolates was carried out on Mueller–Hinton agar (HiMedia Labs, India) using disk-diffusion method according to the guidelines of Clinical and Laboratory Standards Institute (CLSI) [31] using a panel of 10 commercially available antibiotics (LIOFILCHEM, Italy). Information on these antibiotics and their concentrations are shown in Table 1. E. coli ATCC 25922 was used as a control strain.

2.3. Phenotypic Detection of ESBL Production. ESBL production was assessed using the CLSI recommendations for ESBL screening and phenotypic confirmation tests [31]. For initial ESBL screening, UPEC isolates showing an inhibition zone size of ≤22 mm with ceftazidime (30 μg) were identified as potential ESBL producers. The double-disc synergy test (DDST) was carried out for the phenotypic confirmation of ESBL production. For this test, a ceftazidime disc (30 μg) was placed 25 mm away from a combination disc containing ceftazidime-clavulanic acid (30/10 μg). When the zone of inhibition between the combination disc and the corresponding single antibiotic disc differed by ≥5 mm, the strain was identified as an ESBL producer. E. coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 were used as negative and positive control strains, respectively.

2.4. Polymerase Chain Reaction (PCR) of ESBL-Encoding Genes. Bacterial genomic DNA was extracted using the ONE-4-ALL Genomic DNA Mini-Preps Kit (Bio Basic Inc., Canada) according to manufacturer’s instructions. PCR assays were performed to determine the presence of ESBL-encoding genes: blaOXA, blaTEM, blaSHV, and blaCTX-M Groups 1, 2 and 9 using multiplex PCR primer sets (Table 2) and conditions previously described [32].

2.5. DNA Sequencing for Identification of CTX-M ESBL Gene Variants. Automatic DNA sequencing for both strands of all PCR products was carried out using the 3730xL DNA analyzer (ThermoFisher Scientific, United States) to identify the CTX-M ESBL variants. These variants were identified by comparison with the sequences in GenBank (http://blast.ncbi.nlm.nih.gov/Blast.cgi).

3. Results

3.1. Demographic Characteristics of Study Population. A total of 100 urine samples were collected from inpatients during this study period. Among these samples, 76 (76%) belonged to female patients while 24 (24%) belonged to male patients. With regard to the age categories of patients, a total of 60 (60%) samples were collected from adults, 21 (21%) samples belonged to elderly population, and 19 (19%) were obtained from children. Demographic characteristics of patients are shown in Table 3.
3.2. Antimicrobial Susceptibility Profiles and ESBL Prevalence.

Antimicrobial susceptibility testing results are shown in Table 4. Among all antibiotics tested in this study, imipenem was the most active agent as all E. coli isolates were imipenem-susceptible. Out of the 100 E. coli isolates, 92% were resistant to ampicillin, 55% to amoxicillin-clavulanic acid, and 12% to gentamicin. The resistance rates for ceftazidime, cefoxitin, tetracycline, and trimethoprim-sulfamethoxazole were 29%, 13%, 49%, and 54%, respectively. Additionally, 40% and 15% of the isolates were nonsusceptible to ciprofloxacin and nitrofurantoin, respectively.

With regard to ESBL production, initial ESBL screening demonstrated that 41% of all E. coli isolates had an inhibition zone size of ≤22 mm with ceftazidime (30 μg) and therefore initially identified as potential ESBL producers. However, phenotypic confirmation of ESBL production by DDST showed that 33 (33%) of all isolates were confirmed to be ESBL producers, while 67 (67%) isolates were non-ESBL producers. The susceptibility profiles for the ESBL-producing E. coli isolates are shown in Table 3. Of all the 33 E. coli isolates identified as ESBL producers, 29 (88%) were resistant to amoxicillin-clavulanic acid, 28 (85%) to ceftazidime, 27 (82%) to trimethoprim-sulfamethoxazole, and 25 (76%) to ciprofloxacin. Additionally, 9 (27%) isolates were resistant to gentamicin, 6 (18%) to cefoxitin, 23 (70%) to tetracycline, and 7 (21%) to nitrofurantoin. All tested isolates were susceptible to imipenem, while they were all ampicillin-resistant.

For non-ESBL-producing E. coli isolates, the antimicrobial resistance levels were lower than that of ESBL-producing isolates for all antibiotics tested except imipenem. Of all the 67 non-ESBL-producing E. coli isolates, 59 (88%) isolates were resistant to ampicillin, 27 (40%) to trimethoprim-sulfamethoxazole, and 26 (39%) for tetracycline. The antimicrobial resistance rates for other antibiotics ranged from 1.5% for ceftazidime to 22% for ciprofloxacin. All non-ESBL-producing E. coli isolates were imipenem-susceptible.

3.3. Multidrug Resistance (MDR) Phenotype of E. coli Isolates.

Percentage of the clinical E. coli isolates showing MDR phenotype, which is defined as exhibiting resistance to at least 1 agent in ≥3 antimicrobial categories/groups [33], is shown in Figure 1. Our data showed a high level of multidrug resistance among the tested isolates with 67 (67%) of all E. coli isolates showing the MDR phenotype. Of these isolates, 18 (26.86%) isolates were resistant to 3 out of 10 antibiotic groups employed, 17 (25.37%) were nonsusceptible to 4 antibiotic groups, and 10 (14.92%) were nonsusceptible to 5 antibiotic groups.
resistant to 5 antibiotic groups. Additionally, 14 (20.89%), 5 (7.46%), and 2 (2.99%) were resistant to 6, 7, and 8 antibiotics, respectively. There was only 1 (1.49%) isolate that showed resistance to 9 antibiotics while none of the isolates had the ability to show resistance to all the 10 antibiotics used in this study. With respect to the association between ESBL production and the MDR phenotype, our data showed that all the 33 ESBL-positive 
\textit{E. coli} isolates (100%) were MDR; however, only 34 out of the 67 non-ESBL-producing isolates (50.7%) were MDR.

### 3.4. Distribution of ESBL Gene Carriage in \textit{E. coli} Isolates

33 ESBL-producing \textit{E. coli} isolates were tested for the production of the major ESBL genes (\textit{bla}\_\text{OXA}, \textit{bla}\_\text{TEM}, \textit{bla}\_\text{SHV}, and \textit{bla}\_CTX-M, Groups 1, 2, and 9) by PCR. These isolates were all tested positive for ESBL production. The ESBL types detected in the \textit{E. coli} isolates belonged to the CTX-M-Group 1 family, TEM and OXA ESBL genes, while the SHV-type, CTX-M-Group 2, and CTX-M-Group 9 were not detected in any of the tested isolates. The detected ESBL types were either solely or concomitantly harbored by the 33 ESBL-producing \textit{E. coli} isolates. Our data demonstrated that 31 (93.94%) isolates were found to carry the gene encoding for CTX-M-Group 1 and 4 isolates (12.12%) produced the TEM-type ESBL. The CTX-M-Group 1 ESBL was solely carried by 17 isolates, whereas a sole TEM carriage was detected in only 1 isolate.

However, the gene encoding for OXA-type ESBL was not solely detected in any of the tested isolates but rather it was concomitantly produced by 8 isolates (24.24%) that either carry the genes encoding for CTX-M-Group 1, TEM, or both. Additionally, among all ESBL-positive isolates, 15 (45.45%) isolates were associated with multiple ESBL gene carriage. Of these, 11 (33.33%) were able to produce two different ESBL types, while 4 (12.12%) were able to concomitantly produce all the three ESBL types detected in this study. With respect to the CTX-M-Group 1 gene variants, our data showed that the CTX-M-15 variant was present in all the CTX-M-Group 1 producing isolates (Table 5).

### 4. Discussion

The current emergence of multidrug-resistant \textit{E. coli} is becoming a global concern, and infections caused by MDR ESBL-producing \textit{E. coli} represent a major challenge to clinicians and public health worldwide [34]. This study focuses on determining the antimicrobial susceptibility patterns of 100 \textit{E. coli} urine isolates and on characterizing the ESBL carriage of these isolates at both phenotypic and genotypic levels.

Among the 100 urine samples collected in this study, 76 (76%) belonged to female population while 24 (24%) belonged to male patients. The gender distribution of patients in our study is consistent with many previous local [35, 36] and international [37, 38] reports showing the high incidence of UTI in women compared to men across all age groups. It has been demonstrated that the high UTI incidence in women can be attributed to many reasons such as anatomical factors that allow quick access of bacteria to the bladder, poor hygiene, sexual activity, and use of contraceptives [39]. With respect to age group of patients, our data showed that 60% of all study population was adults, followed by elderly (21%). This is in agreement with a recent report demonstrating that UTIs were more common in adults than any other age category [36]. Additionally, adult women were among the most dominant patient group in our study, and they accounted for 46% of total patient number. This concurs with previous studies showing that adult women are 30 times more likely to develop a UTI than men, with almost

---

**Table 4: Antibiotic resistance rates of \textit{E. coli} isolates tested in this study.**

| Antibiotic                              | ESBL producing (n = 33) | Non-ESBL producing (n = 67) | Total (n = 100) |
|-----------------------------------------|-------------------------|------------------------------|-----------------|
| Ampicillin                              | 33 (100%)               | 59 (88%)                     | 92 (92%)        |
| Amoxicillin-clavulanic acid             | 29 (88%)                | 26 (39%)                     | 55 (55%)        |
| Gentamicin                              | 9 (27%)                 | 3 (4.5%)                     | 12 (12%)        |
| Cefazidime                              | 28 (85%)                | 1 (1.5%)                     | 29 (29%)        |
| Cefoxitin                               | 6 (18%)                 | 7 (10.5%)                    | 13 (13%)        |
| Tetracycline                            | 23 (70%)                | 26 (39%)                     | 49 (49%)        |
| Trimethoprim-sulfamethoxazole           | 27 (82%)                | 27 (40%)                     | 54 (54%)        |
| Imipenem                                | 0 (0%)                  | 0 (0%)                       | 0 (0%)          |
| Ciprofloxacin                           | 25 (76%)                | 15 (22%)                     | 40 (40%)        |
| Nitrofurantoin                          | 7 (21%)                 | 8 (12%)                      | 15 (15%)        |
half of them experiencing at least one UTI episode during their lifetime [3].

The antimicrobial susceptibility patterns were determined for all the 100 \textit{E. coli} urine isolates. The ESBL-producing \textit{E. coli} isolates showed higher levels of resistance to all antibiotics compared to the non-ESBL-producing isolates except for imipenem, where all \textit{E. coli} isolates tested in this study were imipenem-sensitive. This is not surprising given that ESBL-producing \textit{E. coli} strains are frequently associated with coresistance to other antimicrobial agents such as aminoglycosides and fluoroquinolones [19]. The ESBL-producing \textit{E. coli} showed the greatest resistance to ampicillin, amoxicillin-clavulanic acid, ceftazidime, trimethoprim-sulphamethoxazole, and ciprofloxacin. This finding is in agreement with many previous reports [30, 40–42] showing that ESBL-producing \textit{E. coli} isolates were more resistant to trimethoprim-sulphamethoxazole, ciprofloxacin, and third-generation cephalosporins compared to non-ESBL-producing \textit{E. coli}, although this resistance did not affect imipenem. This increased resistance levels of ESBL-producing \textit{E. coli} isolates to some front-line antibiotics such as cephalosporins, trimethoprim-sulphamethoxazole, and ciprofloxacin, could be ascribed to the inappropriate and excessive use of these agents in the empirical treatment of UTIs [43]. It has been shown that these antibiotics are commonly used for the treatment of UTIs worldwide [44], and the currently reported increase in resistance trends among uropathogens, primarily \textit{E. coli}, has not only led to high rates of morbidity and mortality [45], but it has also complicated the management of UTIs [46].

In an attempt to achieve the effective treatment of UTIs, several guidelines were reviewed, in the late 2000s, to reposition nitrofurantoin as first-line therapy for community-acquired and nosocomial uncomplicated lower UTI [47, 48]. With respect to \textit{E. coli} resistance to nitrofurantoin, although previous reports showed that it was low in China (1.6%) [49] and in North America (1.1%) [50], it has been reported to be high in Latin American hospitals (13%) [51].

An important worrisome finding in this study is the high rate of resistance to nitrofurantoin (21%) in the ESBL-producing \textit{E. coli}. This is in contrary to many previous local [28] and international studies [49, 50] showing a low prevalence of nitrofurantoin resistance in \textit{E. coli} isolates. The possible explanation of this high nitrofurantoin resistance is

### Table 5: The distribution of β-lactamase genes among ESBL-producing \textit{E. coli} isolates.

| Isolate ID | CTX-M G1 | CTX-M G2 | CTX-M G9 | TEM | OXA | SHV | CTX-M G1 variants |
|------------|---------|---------|---------|-----|-----|-----|--------------------|
| U1         | +       | −       | −       | −   | −   | −   | −                  |
| U4         | +       | −       | −       | −   | −   | −   | −                  |
| U7         | +       | −       | −       | −   | −   | −   | −                  |
| U9         | +       | −       | −       | −   | −   | −   | −                  |
| U10        | +       | −       | −       | −   | −   | −   | −                  |
| U11        | +       | −       | −       | −   | −   | −   | −                  |
| U12        | +       | −       | −       | −   | −   | −   | −                  |
| U15        | +       | −       | −       | −   | −   | −   | −                  |
| U16        | +       | −       | −       | −   | −   | −   | −                  |
| U17        | +       | −       | −       | −   | −   | −   | −                  |
| U20        | +       | −       | −       | −   | −   | −   | −                  |
| U24        | +       | −       | −       | −   | −   | −   | −                  |
| U27        | +       | −       | −       | −   | −   | −   | −                  |
| U28        | +       | −       | −       | −   | −   | −   | −                  |
| U31        | +       | −       | −       | −   | −   | −   | −                  |
| U46        | +       | −       | −       | −   | −   | −   | −                  |
| U55        | +       | −       | −       | +   | −   | −   | −                  |
| U57        | +       | −       | −       | −   | −   | −   | −                  |
| U63        | +       | −       | −       | −   | −   | −   | −                  |
| U65        | +       | −       | −       | +   | −   | −   | −                  |
| U66        | +       | −       | −       | −   | −   | −   | −                  |
| U68        | +       | −       | −       | −   | −   | −   | −                  |
| U71        | +       | −       | −       | −   | −   | −   | −                  |
| U73        | +       | −       | −       | −   | −   | −   | −                  |
| U74        | +       | −       | −       | −   | −   | −   | −                  |
| U75        | −       | −       | −       | +   | −   | −   | −                  |
| U78        | −       | −       | −       | −   | −   | −   | −                  |
| U82        | +       | −       | −       | +   | +   | −   | −                  |
| U85        | +       | −       | −       | −   | −   | −   | −                  |
| U87        | +       | −       | −       | −   | −   | −   | −                  |
| U93        | +       | −       | −       | +   | +   | −   | −                  |
| U95        | −       | −       | −       | +   | +   | −   | −                  |
| U98        | +       | −       | −       | +   | −   | −   | −                  |

1Nonapplicable.
the currently reported exponential global increase in nitrofurantoin prescribing for the empirical treatment of hospitalized patients with positive urine cultures [52].

Based on the suggestion that if the resistance to a particular antibiotic is higher than 20%, that antibiotic should not be prescribed in the empirical antimicrobial treatment [53], and since our data show that the resistance levels of ESBL-producing *E. coli* isolates to 9 out of 10 antibiotics were more than 20%, we propose that carbapenems, such as imipenem, could be the drug of choice to treat UTI patients given that all *E. coli* isolates tested in this study were fully sensitive to imipenem, and this is the case with many recently published reports in Saudi Arabia showing *E. coli* urine isolates with full sensitivity to carbapenems [30, 54].

Additionally, we believe that it is crucial to assess the local antimicrobial resistance rates for specific pathogens and to revise the current guidelines used for optimal local antimicrobial resistance rates for specific pathogens. Recently published reports in Saudi Arabia showing sensitive to imipenem, and this is the case with many reports demonstrating the narrow-spectrum β-lactamase TEM-1, in all ESBL-producing *E. coli* [30].

Currently, CTX-M enzymes have replaced the traditional ESBL types such as SHV and TEM enzymes as the most prevalent ESBL type in *E. coli* [15]. Our study clearly shows that CTX-M enzymes are the dominant ESBLs in Saudi Arabia and that the CTX-M-15 was the most common variant among all CTX-M-Group 1, which is consistent with the previous finding reported by Al-Agamy and colleagues [30].

It has been shown that the successful dissemination of CTX-M-15 enzyme has been attributed to the spread of genetic elements, through horizontal gene transfer, and the clonal expansion of a pandemic *E. coli* clone, *E. coli* ST131 [19], *E. coli* ST131 has been reported worldwide as the most common extraintestinal pathogenic *E. coli* (ExPEC) clone, and this clone is often MDR and is commonly associated with carrying CTX-M-15 enzyme [61, 62]. In the future, it would be important to study the molecular epidemiology of MDR *E. coli* strains to determine the population structure and clonal diversity of currently emerging MDR *E. coli* clones.

Our study has limitations: firstly, it used a low number of *E. coli* isolates that were obtained from a single healthcare facility in Saudi Arabia. Additionally, this study was performed on urine samples collected from hospitalized patients, which affects the accurate assessment of epidemiological changes in the community. Also important is that our study was performed in Riyadh City and this does not necessarily reflect the antimicrobial resistance trends in other regions within Saudi Arabia and that the clinical information of patients included in this study are very scarce.

However, this study shows a high prevalence of ESBL-producing *E. coli* compared to what has been previously reported in Saudi Arabia, with CTX-M-type enzymes being the most predominant ESBL type. Furthermore, our results provide evidence for the predominance of CTX-M-15-producing *E. coli* among UPEC isolates in Saudi Arabia, and this agrees with many reports demonstrating the changing epidemiology of ESBL-producing *E. coli* worldwide.

To conclude, this study demonstrates that *E. coli* isolates are associated with high multidrug resistance rates as well as high ESBL carriage. It also shows that ESBL-producing *E. coli* have high resistance levels to antibiotics, particularly to those used for empirical therapy of UTI patients. This highlights the need to evaluate the local antimicrobial
resistance rates for specific pathogens and to review the current guidelines used for empirical treatment regimens for ESBL-producing uropathogens in order to ensure effective treatment of infections caused by these pathogens.

Abbreviations

ESBL-producing Extended-spectrum \( \beta \)-lactamase-
E. coli: producing *Escherichia coli* 
MDR: Multidrug resistance 
UTIs: Urinary tract infections 
UPEC: Uropathogenic *E. coli* 
CTX-M: “Active on CefoTaXime, first isolated in Munich” 
TEM: ESBL variant isolated from a patient named Temoneira 
SHV: Sulphydryl variable 
OXA: Oxacillin hydrolyzing capabilities 
CLSI: Clinical and Laboratory Standards Institute 
DDST: Double-disc synergy test 
AST: Antimicrobial susceptibility testing 
PCR: Polymerase chain reaction 
\( \mu g \): Microgram 
ST: Sequence type.

Data Availability

All data generated or analyzed during this study are included in this published article and its supplementary information files or available from the corresponding author upon request.

Ethical Approval

The study protocol was reviewed and approved by the Research Ethics Committee at College of Applied Medical Sciences, King Saud University.

Conflicts of Interest

All authors declare that they have no competing interests.

Authors’ Contributions

Abdulaziz Alqasim and Abdullah A. Alyousef contributed to the study design, Abdulaziz Alqasim collected the samples. Abdulaziz Alqasim and Ahmad Abu Jaffal contributed to the laboratory experiments. All authors contributed to the data interpretation. Abdulaziz Alqasim and Abdullah A. Alyousef drafted and revised the manuscript. All the authors read and approved the final manuscript.

Acknowledgments

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through the Research Project no. R17-02-42.

Supplementary Materials

All data generated or analyzed during this study are included in this published article and in the supplementary materials attached. Supplementary materials include the results of antimicrobial susceptibility testing of *E. coli* isolates. (Supplementary Materials)

References

[1] B. Foxman, “The epidemiology of urinary tract infection,” *Nature Reviews Urology*, vol. 7, pp. 653–660, 2010.
[2] A. Cove Smith and M. Almond, “Management of urinary tract infections in the elderly,” *Trends in Urology, Gynaecology & Sexual Health*, vol. 12, no. 4, pp. 31–34, 2007.
[3] B. Foxman, “Epidemiology of urinary tract infections: incidence, morbidity, and economic costs,” *The American Journal of Medicine*, vol. 113, no. 1, pp. 5–13, 2002.
[4] C. M. Gonzalez and A. J. Schaeffer, “Treatment of urinary tract infection: what’s old, what’s new, and what works,” *World Journal of Urology*, vol. 17, no. 6, pp. 372–382, 1999.
[5] J.-S. Huh, “The prevalence of urinary tract infections in institutionalized vs. noninstitutionalized elderly persons,” *Urological Tract Infection*, vol. 11, no. 2, pp. 56–61, 2016.
[6] A. Stapleton, “Prevention of recurrent urinary-tract infections in women,” *The Lancet*, vol. 353, no. 9146, pp. 7–8, 1999.
[7] R. D. Harrington and T. M. Hooton, “Urinary tract infection risk factors and gender,” *The Journal of Gender-Specific Medicine*, vol. 3, pp. 27–34, 2000.
[8] S. Farajnia, M. Y. Alikhani, R. Ghotaslou, B. Naghili, and A. Nakhlband, “Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran,” *International Journal of Infectious Diseases*, vol. 13, no. 2, pp. 140–144, 2009.
[9] R. Kucheria, P. Dasgupta, S. Sacks, M. Khan, and N. Sheerin, “Urinary tract infections: new insights into a common problem,” *Postgraduate Medical Journal*, vol. 81, no. 952, pp. 83–86, 2005.
[10] L. Zhang and B. Foxman, “Molecular epidemiology of *Escherichia coli* mediated urinary tract infections,” *Frontiers in Bioscience*, vol. 8, no. 5, pp. e235–e244, 2003.
[11] G. Croxall, V. Weston, S. Joseph, G. Manning, P. Cheetah, and A. Mcnally, “Increased human pathogenic potential of *Escherichia coli* from polymicrobial urinary tract infections in comparison to isolates from monomicrobial culture samples,” *Journal of Medical Microbiology*, vol. 60, no. 1, pp. 102–109, 2011.
[12] J. D. Pitout, P. Nordmann, K. B. Laupland, and L. Poirel, “Emergence of *Enterobacteriaceae* producing extended-spectrum \( \beta \)-lactamases (ESBLs) in the community,” *Journal of Antimicrobial Chemotherapy*, vol. 56, pp. 52–59, 2005.
[13] M. H. Nicolas-Chanoine, J. Blanco, V. Leflon-Guibout et al., “Intercontinental emergence of *Escherichia coli* clone O25: H4-ST131 producing CTX-M-15,” *Journal of Antimicrobial Chemotherapy*, vol. 61, no. 2, pp. 273–281, 2008.
[14] G. Peirano and J. D. D. Pitout, “Molecular epidemiology of *Escherichia coli* producing CTX-M (beta)-lactamases: the worldwide emergence of clone ST131 O25: H4,” *International Journal of Antimicrobial Agents*, vol. 35, no. 4, pp. 316–321, 2010.
[15] R. Cantón and T. M. Coque, “The CTX-M \( \beta \)-lactamase pandemic,” *Current Opinion in Microbiology*, vol. 9, no. 5, pp. 466–475, 2006.
[16] M. Accogli, T. Giani, M. Monaco et al., “Emergence of Escherichia coli ST131 sub-clone H30 producing VIM-1 and KPC-3 carbapenemases, Italy,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 8, pp. 2293–2296, 2014.

[17] J. C. Cai, R. Zhang, Y. Y. Hu, W. W. Zhou, and G.-X. Chen, “Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase in China,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 1146–1152, 2014.

[18] T. J. Johnson, M. Hargreaves, K. Shaw et al., “Complete genome sequence of a carbapenem-resistant extraintestinal pathogenic Escherichia coli strain belonging to the sequence type 131 H30R subclade,” Genome Announcements, vol. 3, no. 2, pp. 1–2, 2015.

[19] B. A. Rogers, H. E. Sidjabat, and D. L. Paterson, “Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 1, pp. 1–14, 2011.

[20] J. A. Dias Neto, L. D. M. Silva, A. C. P. Martins et al., “Prevalence and bacterial susceptibility of hospital acquired urinary tract infection,” Acta Cirurgica Brasileira, vol. 18, no. 5, pp. 36–38, 2003.

[21] D. Farrell, I. Morrissey, D. de Rubeis, M. Robbins, and D. Felmingham, “A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection,” Journal of Infection, vol. 46, no. 2, pp. 94–100, 2003.

[22] D. Mathai, R. Jones, M. Pfaller, and T. S. G. N. America, “Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America),” Diagnostic Microbiology and Infectious Disease, vol. 40, no. 3, pp. 129–136, 2001.

[23] S. Ahmad, N. F. Al-Juaid, F. Q. Alenzi, E. H. Mattar, and O. E.-S. Bakheet, “Prevalence, antibiotic susceptibility pattern and production of extended-spectrum β-lactamases amongst clinical isolates of Klebsiella pneumoniae at Armed Forces Hospital in Saudi Arabia,” Journal of the College of Physicians and Surgeons Pakistan, vol. 19, pp. 264-265, 2009.

[24] M. Al-Agamy, A. Shibl, and A. Tawfik, “Prevalence and molecular characterization of extended-spectrum [beta]-lactamase-producing Klebsiella pneumoniae in Riyadh, Saudi Arabia,” Annals of Saudi Medicine, vol. 29, no. 4, pp. 253–257, 2009.

[25] A. A. Kader and A. Kumar, “Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital,” Annals of Saudi Medicine, vol. 25, no. 3, pp. 239–242, 2005.

[26] A. M. Shibl, M. H. Al-Agamy, H. Khubnani, A. C. Senok, A. F. Tawfik, and D. M. Livemore, “High prevalence of acquired quinolone-resistance genes among Enterobacteriaceae from Saudi Arabia with CTX-M-15 β-lactamase,” Diagnostic Microbiology and Infectious Disease, vol. 73, no. 4, pp. 350–353, 2012.

[27] A. F. Tawfik, A. M. Alswailem, A. M. Shibl, and M. H. Al-Agamy, “Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical Klebsiella pneumoniae isolates from Saudi Arabia,” Microbial Drug Resistance, vol. 17, no. 3, pp. 383–388, 2011.

[28] F. E. Al Otaibi and E. E. Bukhari, “Clinical and laboratory profiles of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care center in central Saudi Arabia,” Saudi Medical Journal, vol. 34, pp. 171–176, 2013.

[29] M. H. Al-Agamy, A. M. Shibl, N. A. Elkhizzi, D. Meunier, J. F. Turton, and D. M. Livemore, “Persistence of Klebsiella pneumoniae clones with OXA-48 or NDM carbapenemases causing bacteraemia in a Riyadh hospital,” Diagnostic Microbiology and Infectious Disease, vol. 76, no. 2, pp. 214–216, 2013.

[30] M. H. Al-Agamy, A. M. Shibl, M. M. Hafez, M. N. Al-Ahdal, Z. A. Memish, and H. Khubnani, “Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in Riyadh: emergence of CTX-M-15-producing E. coli ST131,” Annals of Clinical Microbiology and Antimicrobials, vol. 13, no. 1, pp. 1–7, 2014.

[31] Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing 28th Information Supplement (M100–S28), Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2018.

[32] C. Dallenne, A. da Costa, D. Decré, C. Favier, and G. Arlet, “Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 3, pp. 490–495, 2010.

[33] A. P. Maji, A. Srinivasan, R. Carey et al., “Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance,” Clinical Microbiology and Infection, vol. 18, no. 3, pp. 268–281, 2012.

[34] D. Paterson, “Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs),” Clinical Microbiology and Infection, vol. 6, no. 9, pp. 460–463, 2000.

[35] S. Al-Mjjali, “Bacterial uropathogens in urinary tract infection and antibiotic susceptibility pattern in Riyadh Hospital, Saudi Arabia,” Cellular & Molecular Medicine, vol. 3, no. 1, pp. 1–6, 2017.

[36] M. Q. Alanaiz, F. Y. Alaqthani, and F. S. Aleanizy, “An evaluation of E. coli in urinary tract infection in emergency department at KAMC in Riyadh, Saudi Arabia: retrospective study,” Annals of Clinical Microbiology and Antimicrobials, vol. 17, no. 1, pp. 1–7, 2018.

[37] M. C. Raynor, “Urinary infections in men,” The Medical Clinics of North America, vol. 95, no. 1, pp. 43–54, 2011.

[38] T. A. Rowe and M. Juthani-Mehta, “Urinary tract infection in older adults,” Aging Health, vol. 9, no. 5, pp. 519–528, 2013.

[39] A. S. John, C. I. Mboyo, and B. Agbo, “A review on the prevalence and predisposing factors responsible for urinary tract infection among adults,” European Journal of Experimental Biology, vol. 6, pp. 7–11, 2016.

[40] A. A. Ahmed, H. Osman, A. M. Mansour et al., “Antimicrobial agent resistance in bacterial isolates from patients with diarrhea and urinary tract infection in the Sudan,” The American Journal of Tropical Medicine and Hygiene, vol. 63, no. 5, pp. 259–263, 2000.

[41] Ö. Azap, H. Arslan, K. Şerefnanoğlu et al., “Risk factors for extended-spectrum β-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections,” Clinical Microbiology and Infection, vol. 16, no. 2, pp. 147–151, 2010.

[42] S. J. Moyo, S. Aboud, M. Kasubi, E. F. Lyamuya, and S. Y. Maselle, “Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania,” BMC Research Notes, vol. 3, no. 1, p. 348, 2010.

[43] A. AbuDuzaimovic, M. Aljicevic, V. Rebic, S. M. Vranic, K. AbuDuzaimovic, and S. Sestic, “Antibiotic resistance in
International Journal of Microbiology

Y. Taur and M. A. Smith, "Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection," *Clinical Infectious Diseases*, vol. 44, no. 6, pp. 769–774, 2007.

M. Tumbarello, M. Sanguinetti, E. Montuaori et al., "Predictors of mortality in patients with bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment," *Antimicrobial Agents and Chemotherapy*, vol. 51, no. 6, pp. 1987–1994, 2007.

T. M. Hooton, R. Besser, B. Foxman, T. R. Fritsche, and M. Tumbarello, M. Sanguinetti, E. Montuaori et al., "Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase–producing *Escherichia coli*: results of the CANWARD 2007–2009 study," *Diagnostic Microbiology and Infectious Disease*, vol. 69, no. 3, pp. 326–334, 2011.

A. D. Celik, Z. Yulugkural, F. Kuloğlu et al., "CTX-M type extended spectrum β-lactamases in *Escherichia coli* isolates from community acquired upper urinary tract infections at a university in the european part of Turkey," *Journal of Microbiology, Immunology and Infection*, vol. 43, no. 2, pp. 163–167, 2010.

A. Pathak, Y. Marothi, V. Kekre, K. Mahadik, R. Macaden, and C. S. Lundborg, "High prevalence of extended-spectrum β-lactamase–producing pathogens: results of a surveillance study in two hospitals in Ujjain, India," *Infection and Drug Resistance*, vol. 5, pp. 65–73, 2012.

N. Al Mously, O. Al Afraj, L. Al Fadhil, and S. Mukaddam, "Antimicrobial susceptibility patterns of ESBL *Escherichia coli* isolated from community and hospital-acquired urinary tract infections," *Journal of Health Specialties*, vol. 4, no. 2, pp. 133–139, 2016.

H. Dhanji, M. Doumith, O. Clermont et al., "Real-time PCR for detection of the O25b-ST131 clone of *Escherichia coli* and its CTX-M-15-like extended-spectrum β-lactamases," *International Journal of Antimicrobial Agents*, vol. 36, no. 4, pp. 355–358, 2010.

S. Vimont, A. Boyd, A. Bleibtreu et al., "The CTX-M-15-producing *Escherichia coli* clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities," *PloS One*, vol. 7, no. 9, pp. 1–10, 2012.

L. E. Nicolle, "Urinary tract infection: traditional pharmacologic therapies,” *The American Journal of Medicine*, vol. 113, no. 1, pp. 35–44, 2002.

E. J. Alyamani, A. M. Khiyami, R. Y. Boorq, M. A. Majrashi, F. S. Bahwerth, and E. Rechkina, "The occurrence of ESBL-producing *Escherichia coli* carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia,” *Annals of Clinical Microbiology and Antimicrobials*, vol. 16, no. 1, pp. 1–13, 2017.

S. Bouchillon, B. Johnson, D. Hoban et al., "Determining incidence of extended spectrum β-lactamase producing *Enterobacteriaceae*, vancomycin-resistant *Enterococcus faecium* and methicillin-resistant *Staphylococcus aureus* in 38 centres from 17 countries: the PEARLS study 2001–2002,” *International Journal of Antimicrobial Agents*, vol. 24, no. 2, pp. 119–124, 2004.